BR112015013525A2 - a method for producing a fusion protein as well as a composition comprising a fusion protein - Google Patents
a method for producing a fusion protein as well as a composition comprising a fusion proteinInfo
- Publication number
- BR112015013525A2 BR112015013525A2 BR112015013525A BR112015013525A BR112015013525A2 BR 112015013525 A2 BR112015013525 A2 BR 112015013525A2 BR 112015013525 A BR112015013525 A BR 112015013525A BR 112015013525 A BR112015013525 A BR 112015013525A BR 112015013525 A2 BR112015013525 A2 BR 112015013525A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion protein
- methods
- fusion proteins
- peptides
- producing
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/99—Miscellaneous (1.14.99)
- C12Y114/99003—Heme oxygenase (1.14.99.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Abstract
abstract of the disclosure methods and systems for producing fusion proteins and peptides are disclosed. fusion proteins and peptides created using the methods are also provided. also provided are methods of using the fusion proteins and peptides produced according to the present disclosure. tradução do resumo resumo patente de invenção: "parceiros de fusão de lipocalina". métodos e sistemas para a produção de proteínas e peptídeos de fusão são descritos. proteínas e peptídeos de fusão criados usando os métodos também são fornecidos. são também fornecidos métodos de uso das proteínas e peptídeos de fusão produzidos de acordo com a presente descriçãoabstract of the disclosure methods and systems for producing fusion proteins and peptides are disclosed. Fusion proteins and peptides created using the methods are also provided. Also provided are methods of using the fusion proteins and peptides produced according to the present disclosure. abstract of the patent abstract: "lipocalin fusion partners". Methods and systems for the production of fusion proteins and peptides are described. Fusion proteins and peptides created using the methods are also provided. Methods of using fusion proteins and peptides produced according to the present disclosure are also provided.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261735516P | 2012-12-10 | 2012-12-10 | |
US201361794685P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/074215 WO2014093403A1 (en) | 2012-12-10 | 2013-12-10 | Lipocalin fusion partners |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015013525A2 true BR112015013525A2 (en) | 2017-11-14 |
Family
ID=49883268
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015013515A BR112015013515A2 (en) | 2012-12-10 | 2013-12-10 | methods of generating a mass-defined drug candidate library, and for identifying peptides having a pharmacological property |
BR112015013525A BR112015013525A2 (en) | 2012-12-10 | 2013-12-10 | a method for producing a fusion protein as well as a composition comprising a fusion protein |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015013515A BR112015013515A2 (en) | 2012-12-10 | 2013-12-10 | methods of generating a mass-defined drug candidate library, and for identifying peptides having a pharmacological property |
Country Status (11)
Country | Link |
---|---|
US (4) | US20150316536A1 (en) |
EP (2) | EP2928914A1 (en) |
JP (2) | JP2016505826A (en) |
CN (2) | CN105008393A (en) |
AU (2) | AU2013359426A1 (en) |
BR (2) | BR112015013515A2 (en) |
CA (2) | CA2913127A1 (en) |
IL (2) | IL239262A0 (en) |
RU (2) | RU2015126651A (en) |
SG (2) | SG11201504602VA (en) |
WO (2) | WO2014093406A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2799169C (en) | 2010-05-11 | 2019-07-23 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
KR102238317B1 (en) | 2012-05-17 | 2021-04-12 | 익스텐드 바이오사이언시즈, 인크. | Carriers for improved drug delivery |
WO2014093406A1 (en) | 2012-12-10 | 2014-06-19 | Fred Hutchinson Cancer Research Center | Methods for screening |
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
KR101576904B1 (en) * | 2014-07-31 | 2015-12-14 | (주)케어젠 | Peptides Having Activities for Inhibiting Differentiation and Activity of Osteoclast and Uses Thereof |
WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
JP6947642B2 (en) * | 2015-05-18 | 2021-10-13 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Anti-cancer fusion polypeptide |
JP2018521994A (en) * | 2015-06-26 | 2018-08-09 | フレッド ハッチンソン キャンサー リサーチ センター | Therapeutic peptides and methods for their use |
EP3313427A4 (en) * | 2015-06-26 | 2018-12-26 | Fred Hutchinson Cancer Research Center | Therapeutic peptides and methods of use thereof |
BR112018004536A2 (en) * | 2015-09-09 | 2018-12-11 | Blaze Bioscience Inc | cartilage addressing peptides |
EP3373952A4 (en) | 2015-11-10 | 2019-05-22 | Fred Hutchinson Cancer Research Center | Nkg2d decoys |
CN105348392B (en) * | 2015-11-18 | 2019-08-02 | 北京华金瑞清生物医药技术有限公司 | A kind of Nav1.7 inhibitor and its remodeling method |
AU2017250359B2 (en) | 2016-04-15 | 2022-06-16 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
EP3442555A4 (en) * | 2016-04-15 | 2020-04-01 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
US20190292243A1 (en) * | 2016-08-22 | 2019-09-26 | Fred Hutchinson Cancer Research Center | Peptides and methods of use thereof |
EP3503930A4 (en) | 2016-08-29 | 2020-08-05 | Fred Hutchinson Cancer Research Center | Chelating platform for delivery of radionuclides |
CN106699866A (en) * | 2016-12-13 | 2017-05-24 | 山西农业大学 | Chicken Ex-FABP (extracellular fatty acid-binding protein), prokaryotic expression and purification method of chicken Ex-FABP |
AU2018210157B2 (en) | 2017-01-18 | 2022-10-06 | Fred Hutchinson Cancer Center | Peptide compositions and methods of use thereof for disrupting TEAD interactions |
AU2018236465A1 (en) * | 2017-03-16 | 2019-08-22 | Blaze Bioscience, Inc. | Cartilage-homing peptide conjugates and methods of use thereof |
CA3064436A1 (en) | 2017-06-15 | 2018-12-20 | Blaze Bioscience, Inc. | Renal-homing peptide conjugates and methods of use thereof |
CN107739410B (en) * | 2017-10-18 | 2021-07-30 | 南京鼓楼医院 | CD3 single-chain antibody-iRGD fusion protein, preparation and application thereof as antitumor drug |
US11866466B2 (en) | 2017-12-19 | 2024-01-09 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
US20210171589A1 (en) * | 2018-03-16 | 2021-06-10 | Blaze Bioscience, Inc. | Truncated cartilage-homing peptides and peptide complexes and methods of use thereof |
AU2020407558A1 (en) * | 2019-12-19 | 2022-03-17 | Blaze Bioscience, Inc. | Methods of treating vascular lesions and malformations |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
DE3407582A1 (en) | 1984-03-01 | 1985-09-05 | Dornier System Gmbh, 7990 Friedrichshafen | CIRCUIT ARRANGEMENT FOR A CONTROL LOOP |
EP0282581A4 (en) | 1986-09-19 | 1988-11-02 | Scripps Clinic Res | Monoclonal paratopic molecule directed to human ganglioside gd2. |
US5591829A (en) | 1987-05-29 | 1997-01-07 | Matsushita; Shuzo | Antibodies modified with toxic substance |
US5051364A (en) | 1989-02-16 | 1991-09-24 | The Salk Institute For Biological Studies | Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies |
DE3909799A1 (en) | 1989-03-24 | 1990-09-27 | Behringwerke Ag | MONOCLONAL ANTIBODIES (MAK) AGAINST TUMOR ASSOCIATED ANTIGENS, THEIR PRODUCTION AND USE |
CA2066428C (en) | 1989-09-08 | 2000-11-28 | Bert Vogelstein | Structural alterations of the egf receptor gene in human gliomas |
US5223253A (en) | 1989-09-28 | 1993-06-29 | American Home Products Corporation | Bovine vaccine compositions and method for preventing trichomonas infections using same |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
GB2250993B (en) | 1990-11-21 | 1995-02-15 | Inst Nat Sante Rech Med | Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer |
US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
EP1243652A3 (en) | 1991-09-20 | 2003-03-26 | Amgen Inc., | Glial derived neurotrophic factor |
US5314992A (en) | 1991-11-25 | 1994-05-24 | Trustees Of Dartmouth College | Lipocortin-1 receptor protein and its uses |
WO1993023075A1 (en) | 1992-05-14 | 1993-11-25 | Oncologix, Inc. | Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors |
KR100352046B1 (en) | 1993-01-14 | 2003-09-03 | 캔써 리서치 캠페인 테크놀로지 리미티드 | Pharmaceutical combination preparations for strengthening temozolomide in human tumor cells |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5688773A (en) | 1994-08-17 | 1997-11-18 | The General Hospital Corporation | Method of selectively destroying neoplastic cells |
US5985822A (en) | 1994-12-09 | 1999-11-16 | The Scripps Research Institute | Inhibition of glial cell proliferation with N-CAM homophilic peptides |
US5756340A (en) | 1995-05-08 | 1998-05-26 | The Regents Of The University Of California | Insect control with multiple toxins |
JP3809502B2 (en) | 1995-05-30 | 2006-08-16 | 二郎 有川 | Hantavirus antigen protein and monoclonal antibody |
JPH0971599A (en) | 1995-09-06 | 1997-03-18 | Nippon Seibutsu Kagaku Kenkyusho | Polypeptide capable of manifesting high reactivity with chicken blood serum infected with chicken anemic virus (cav), antibody against the same polypeptide, diagnosis and vaccine for infection with chicken anemic virus |
US6667156B2 (en) | 1995-12-27 | 2003-12-23 | Uab Research Foundation | Diagnosis and treatment of neuroectodermal tumors |
US5905027A (en) | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
AU2889097A (en) * | 1996-05-10 | 1997-12-05 | Novartis Ag | Identification of members of combinatorial libraries by mass spectrometry |
US6130101A (en) | 1997-09-23 | 2000-10-10 | Molecular Probes, Inc. | Sulfonated xanthene derivatives |
CN1284083A (en) | 1997-12-05 | 2001-02-14 | 伊东恭悟 | Tumor antigen peptide derivatives |
GB9809776D0 (en) | 1998-05-07 | 1998-07-08 | Nycomed Imaging As | Method |
WO2000009502A1 (en) | 1998-08-12 | 2000-02-24 | Daiichi Pure Chemicals Co., Ltd. | Fluorescent labelling reagents |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
DE69912444T3 (en) | 1998-08-25 | 2010-05-06 | University Of Washington, Seattle | FAST QUANTITATIVE ANALYSIS OF PROTEINS OR PROTEIN FUNCTIONS IN COMPLEX MIXTURES |
US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
US6629040B1 (en) * | 1999-03-19 | 2003-09-30 | University Of Washington | Isotope distribution encoded tags for protein identification |
SE9901387D0 (en) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
EP1216060A2 (en) | 1999-09-14 | 2002-06-26 | Biomedical Apherese Systeme GmbH | Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
AUPQ339899A0 (en) * | 1999-10-13 | 1999-11-04 | University Of Queensland, The | Novel molecules |
AU4305101A (en) | 1999-11-22 | 2001-06-04 | Research Foundation Of The State University Of New York, The | Magnetic nanoparticles for selective therapy |
DE10020376A1 (en) | 2000-04-26 | 2001-11-08 | Inst Zelltechnologie E V | Dynamic markers |
WO2002036142A2 (en) | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
US20020077921A1 (en) | 2000-12-15 | 2002-06-20 | Paul-David Morrison | Method and apparatus for an interactive catalog |
WO2002069896A2 (en) | 2001-03-01 | 2002-09-12 | Northwest Hospital | Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation |
WO2003008583A2 (en) | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
GB0115581D0 (en) * | 2001-06-26 | 2001-08-15 | Glaxo Group Ltd | Method of mass spectometry |
US20030021810A1 (en) | 2001-06-26 | 2003-01-30 | Sontheimer Harald W. | Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling |
WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
US6972326B2 (en) | 2001-12-03 | 2005-12-06 | Molecular Probes, Inc. | Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes |
US7094868B2 (en) | 2002-02-04 | 2006-08-22 | Auburn University | Peptides for recognition and targeting of GLIAL cell tumors |
US20030232013A1 (en) | 2002-02-22 | 2003-12-18 | Gary Sieckman | Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides |
CA2494451A1 (en) | 2002-05-31 | 2003-12-11 | Transmolecular, Inc. | Treatment of cell proliferative disorders with chlorotoxin |
US20060088899A1 (en) | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
US7563600B2 (en) * | 2002-09-12 | 2009-07-21 | Combimatrix Corporation | Microarray synthesis and assembly of gene-length polynucleotides |
US7560160B2 (en) | 2002-11-25 | 2009-07-14 | Materials Modification, Inc. | Multifunctional particulate material, fluid, and composition |
US20040101822A1 (en) | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
US20050059038A1 (en) | 2003-03-21 | 2005-03-17 | Adams Steven P. | Method of screening for target ligands |
CN1791671A (en) * | 2003-03-21 | 2006-06-21 | 先灵公司 | Method of screening for target ligands |
EP1639090A4 (en) | 2003-06-09 | 2008-04-16 | Univ Michigan | Compositions and methods for treating and diagnosing cancer |
DE10328251A1 (en) | 2003-06-24 | 2005-01-13 | Toximed Gmbh | Pharmaceutical agent |
US20070275902A1 (en) | 2003-11-26 | 2007-11-29 | Transmolecular, Inc. | Treatment of Phosphatidylinositol Phospholipid Disorders |
ATE428779T1 (en) * | 2003-12-18 | 2009-05-15 | Biomethodes | METHOD FOR SITE-SPECIFIC MASS MUtagenesis |
ES2339683T3 (en) | 2004-04-06 | 2010-05-24 | Transmolecular, Inc. | DIAGNOSIS AND TREATMENT OF CANELS OF MYELOID CELLS AND LINFOIDS. |
US20080153746A1 (en) | 2004-04-06 | 2008-06-26 | Transmolecular, Inc. | Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers |
JP2007536260A (en) | 2004-05-06 | 2007-12-13 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | NGAL for reducing and improving ischemic and nephrotoxic disorders |
MX2007000728A (en) | 2004-07-21 | 2007-03-15 | Ambrx Inc | Biosynthetic polypeptides utilizing non-naturally encoded amino acids. |
WO2006036928A2 (en) * | 2004-09-27 | 2006-04-06 | Wayne State University | Inhibitors of matrix metalloproteinases to treat neurological disorders |
GB0422901D0 (en) * | 2004-10-14 | 2004-11-17 | Ares Trading Sa | Lipocalin protein |
KR100681763B1 (en) | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 2 A therapeutic agent comprising lipocalin 2 against cancer metastasis and methods of early diagnosis and inhibition of cancer metastasis using lipocalin 2 |
GB0504767D0 (en) * | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
US7462446B2 (en) | 2005-03-18 | 2008-12-09 | University Of Washington | Magnetic nanoparticle compositions and methods |
US20070037232A1 (en) | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
EP1871911A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Cancer-related genes (prlr) |
WO2006110582A1 (en) | 2005-04-08 | 2006-10-19 | Xcyte Therapies, Inc. | Compositions and methods for the treatment of burns and sepsis |
DE602006020710D1 (en) | 2005-04-22 | 2011-04-28 | Fred Hutchinson Cancer Res Foundation | FLUORESCENT CHLOROTOXIN CONJUGATE AND METHOD FOR THE INTRAOPERATIVE VIEW OF CANCER |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
CN103103238B (en) | 2005-08-18 | 2016-08-10 | Ambrx公司 | A kind of manufacture in cell has selected amino acid whose antibody or the method for antibody fragment polypeptide in specific location |
WO2007117467A2 (en) | 2006-03-31 | 2007-10-18 | Transmolecular, Inc. | Use of tm-601 for the diagnosis and treatment of tumors |
EP2029157A4 (en) | 2006-05-19 | 2009-11-18 | Georgia Tech Res Inst | Abc transporter ligand |
CN100564517C (en) | 2006-09-21 | 2009-12-02 | 武汉大学 | A kind of anti-glioma peptide of scorpion and its production and application |
CN101003788A (en) | 2006-09-21 | 2007-07-25 | 武汉大学 | Anti tumor translocation peptide of scorpion, preparation method and application |
PE20081140A1 (en) | 2006-10-25 | 2008-09-22 | Amgen Inc | THERAPEUTIC AGENTS BASED ON PEPTIDES DERIVED FROM TOXINS |
ATE502114T1 (en) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | BIOLOGICALLY ACTIVE PROTEINS WITH INCREASED IN-VIVO AND/OR IN-VITRO STABILITY |
US20090004105A1 (en) | 2007-06-27 | 2009-01-01 | Zhen Cheng | Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin |
AU2008285364A1 (en) | 2007-08-07 | 2009-02-12 | Transmolecular, Inc. | Chlorotoxins as drug carriers |
WO2009029760A1 (en) | 2007-08-31 | 2009-03-05 | Iosemantics, Llc | Quality assurance tools for use with source code and a semantic model |
WO2009049184A2 (en) | 2007-10-12 | 2009-04-16 | Transmolecular, Inc. | Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors |
US20090124022A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Antibodies that bind to mammalian ngal and uses thereof |
US20090123946A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
JP2011501673A (en) | 2007-10-19 | 2011-01-13 | アボット・ラボラトリーズ | Glycosylated mammalian NGAL and uses thereof |
US20090123970A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
US20090176274A1 (en) | 2007-10-19 | 2009-07-09 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
US20090269777A1 (en) | 2007-10-19 | 2009-10-29 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
US8846036B2 (en) | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
ES2475990T5 (en) | 2007-11-15 | 2017-07-06 | Bioporto Diagnostics A/S | Diagnostic use of individual molecular forms of a biomarker |
DK2244741T3 (en) | 2008-01-18 | 2015-05-26 | Visen Medical Inc | Fluorescent imaging agents |
US9308239B2 (en) | 2008-02-26 | 2016-04-12 | The Penn State Research Foundation | Methods and compositions for treatment of retinoid-responsive conditions |
US8093060B2 (en) | 2008-02-28 | 2012-01-10 | Canon Kabushiki Kaisha | Multisite phosphorylated peptide (protein) recognizing compound and detection method, imaging method, alzheimer's disease diagnosing method and reagent kit using the same |
US8685370B2 (en) | 2008-03-14 | 2014-04-01 | Visen Medical, Inc. | Integrin targeting agents and in-vivo and in-vitro imaging methods using the same |
AU2008352925A1 (en) | 2008-03-20 | 2009-09-24 | Transmolecular, Inc. | Inhibition of angiogenesis |
GB0807831D0 (en) | 2008-04-29 | 2008-06-04 | Cambridge Entpr Ltd | Agents for imaging cell death |
CN101270158B (en) | 2008-04-30 | 2010-12-22 | 武汉大学 | Target glioma resistant protein, preparation method and application |
EP2300045A1 (en) | 2008-05-15 | 2011-03-30 | Transmolecular, Inc. | Treatment of metastatic tumors |
JP2009300110A (en) | 2008-06-10 | 2009-12-24 | Olympus Corp | Optical detection method or imaging method of transplantation cell |
JP5711118B2 (en) * | 2008-06-24 | 2015-04-30 | テクニッシュ ウニヴェルジテート ミュンヘン | HNGAL and affinity protein muteins with affinity for a given target |
US20100098637A1 (en) | 2008-09-23 | 2010-04-22 | The Regents Of The University Of Michigan | Dye-loaded nanoparticle |
CN101381405B (en) | 2008-09-24 | 2011-07-27 | 武汉摩尔生物科技有限公司 | Genetic engineering tumor targeting KCT-W1 polypeptides and preparation method and application |
JP2010085108A (en) | 2008-09-29 | 2010-04-15 | Nano Factory:Kk | Probe for imaging biolight |
US20100105150A1 (en) | 2008-10-24 | 2010-04-29 | Abbott Laboratories | Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal |
US20100331650A1 (en) * | 2009-06-25 | 2010-12-30 | Roche Diagnostics Operations, Inc. | Episodic blood glucose monitoring system with an interactive graphical user interface and methods thereof |
CN102791827B (en) | 2009-11-09 | 2016-11-16 | 华盛顿大学商业化中心 | Functionalization chromophoric polymers point and bioconjugate body thereof |
CN101921769B (en) | 2010-01-11 | 2012-07-25 | 山西大学 | Recombinant adenovirus, preparation method and application thereof |
WO2011094671A2 (en) | 2010-01-29 | 2011-08-04 | The Uab Research Foundation | N-terminally conjugated polypeptides for targeted therapy and diagnosis |
KR101923235B1 (en) | 2010-02-04 | 2018-11-28 | 에이자이 아이엔씨. | Chlorotoxin polypeptides and conjugates and uses thereof |
CN101824084A (en) | 2010-04-08 | 2010-09-08 | 山西大学 | Targeting antiglioma protein and application thereof |
CA2799169C (en) | 2010-05-11 | 2019-07-23 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
CN103154023B (en) * | 2010-08-16 | 2017-04-05 | 皮里斯制药有限公司 | The associated proteins of hepcidin |
DK2638173T3 (en) | 2010-11-08 | 2019-09-30 | Univ Leland Stanford Junior | FUSION PROTEINS INCLUDING A MANIPULATED KNOTTIN PEPTIDE AND APPLICATIONS THEREOF |
CN103392219B (en) | 2010-12-28 | 2017-02-08 | 探索诊断投资公司 | Quantitation of insulin by mass spectrometry |
WO2013036810A1 (en) * | 2011-09-07 | 2013-03-14 | X-Chem, Inc. | Methods for tagging dna-encoded libraries |
WO2014093406A1 (en) | 2012-12-10 | 2014-06-19 | Fred Hutchinson Cancer Research Center | Methods for screening |
-
2013
- 2013-12-10 WO PCT/US2013/074218 patent/WO2014093406A1/en active Application Filing
- 2013-12-10 EP EP13814726.9A patent/EP2928914A1/en not_active Withdrawn
- 2013-12-10 CN CN201380072527.9A patent/CN105008393A/en active Pending
- 2013-12-10 BR BR112015013515A patent/BR112015013515A2/en not_active IP Right Cessation
- 2013-12-10 US US14/651,172 patent/US20150316536A1/en not_active Abandoned
- 2013-12-10 AU AU2013359426A patent/AU2013359426A1/en not_active Abandoned
- 2013-12-10 AU AU2013359429A patent/AU2013359429A1/en not_active Abandoned
- 2013-12-10 CA CA2913127A patent/CA2913127A1/en not_active Abandoned
- 2013-12-10 BR BR112015013525A patent/BR112015013525A2/en not_active IP Right Cessation
- 2013-12-10 RU RU2015126651A patent/RU2015126651A/en not_active Application Discontinuation
- 2013-12-10 CN CN201380072523.0A patent/CN105189540A/en active Pending
- 2013-12-10 RU RU2015126650A patent/RU2015126650A/en not_active Application Discontinuation
- 2013-12-10 CA CA2913029A patent/CA2913029A1/en not_active Abandoned
- 2013-12-10 SG SG11201504602VA patent/SG11201504602VA/en unknown
- 2013-12-10 WO PCT/US2013/074215 patent/WO2014093403A1/en active Application Filing
- 2013-12-10 JP JP2015545941A patent/JP2016505826A/en not_active Ceased
- 2013-12-10 US US14/651,175 patent/US10156559B2/en active Active
- 2013-12-10 JP JP2015545938A patent/JP2016505251A/en active Pending
- 2013-12-10 SG SG11201504600UA patent/SG11201504600UA/en unknown
- 2013-12-10 EP EP13814341.7A patent/EP2928913A1/en not_active Withdrawn
- 2013-12-10 US US14/102,396 patent/US20140179560A1/en not_active Abandoned
-
2015
- 2015-06-07 IL IL239262A patent/IL239262A0/en unknown
- 2015-06-07 IL IL239261A patent/IL239261A0/en unknown
-
2018
- 2018-12-11 US US16/216,625 patent/US20190101528A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2013359426A1 (en) | 2015-07-09 |
US20150316536A1 (en) | 2015-11-05 |
AU2013359426A2 (en) | 2015-11-05 |
US20190101528A1 (en) | 2019-04-04 |
IL239262A0 (en) | 2015-07-30 |
WO2014093403A1 (en) | 2014-06-19 |
EP2928914A1 (en) | 2015-10-14 |
SG11201504602VA (en) | 2015-07-30 |
BR112015013515A2 (en) | 2017-11-14 |
AU2013359429A1 (en) | 2015-07-09 |
CN105189540A (en) | 2015-12-23 |
US20140179560A1 (en) | 2014-06-26 |
CN105008393A (en) | 2015-10-28 |
RU2015126650A (en) | 2017-01-12 |
WO2014093406A1 (en) | 2014-06-19 |
CA2913127A1 (en) | 2014-06-19 |
EP2928913A1 (en) | 2015-10-14 |
SG11201504600UA (en) | 2015-07-30 |
RU2015126651A (en) | 2017-01-16 |
CA2913029A1 (en) | 2014-06-19 |
AU2013359429A2 (en) | 2015-11-12 |
IL239261A0 (en) | 2015-07-30 |
US20150322123A1 (en) | 2015-11-12 |
JP2016505251A (en) | 2016-02-25 |
JP2016505826A (en) | 2016-02-25 |
US10156559B2 (en) | 2018-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015013525A2 (en) | a method for producing a fusion protein as well as a composition comprising a fusion protein | |
MX2020006117A (en) | Targeted integration of nucleic acids. | |
PE20150645A1 (en) | INTERLEUQUIN 10 FUSION PROTEINS AND USES OF THEM | |
BR112017018975A2 (en) | fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for il15ra and therapeutic uses thereof. | |
BR112015004467A2 (en) | method for controlling protein heterogeneity | |
PH12014502767A1 (en) | Interleukin-2 fusion proteins and uses thereof | |
BR112015022208A8 (en) | fusion proteins comprising pdgf and vegf binding moieties, and methods of using it | |
MX2015008446A (en) | Multivalent binding protein compositions. | |
BR112014008694A2 (en) | recombinant polycistronic nucleic acid molecules | |
SG10201805291TA (en) | Production of heterodimeric proteins | |
BR112015011389A2 (en) | RESPIRATORY SYNCYTIAL VIRUS F COMPLEX, METHODS FOR PRODUCING A RESPIRATORY SYNCYCIAL VIRUS F COMPLEX AND FOR INDUCING AN IMMUNOLOGICAL RESPONSE TO AN RSV F IN AN INDIVIDUAL, AND, IMMUNOGENIC COMPOSITION | |
AR090047A1 (en) | DUAL VARIABLE DOMAIN OF IMMUNOGLOBULINS AND THEIR USES | |
AU2012257942A8 (en) | Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same | |
CO6781540A2 (en) | Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a | |
TR201905619T4 (en) | Peptide carrier fusion proteins as allergy vaccines. | |
WO2012068317A3 (en) | Methods for producing recombinant proteins | |
BR112014015933A2 (en) | methods and materials to reduce recombinant protein degradation | |
BR112015021993A2 (en) | Antioxidant cell culture compositions and methods for producing polypeptide | |
EA201491784A1 (en) | Antibodies Against Ligand Recorder B1 Bradykinin | |
BR112016006606A2 (en) | RECOMBINANT NUCLEIC ACID MOLECULE, RECOMBINANT AMINO ACID MOLECULE, RECOMBINANT EXPRESSION CONSTRUCTION, RECOMBINANT VECTOR, RECOMBINANT MICROORGANISM, COMPOSITION, AMINO ACIDS PRODUCTION METHOD, USE OF A NUCLEIC ACID MOLECULE AND FERMENTATIVE PRODUCTION PROCESS | |
PH12015501687A1 (en) | Novel binding proteins from pcsk9 | |
BR112013004124A2 (en) | alpha2 integrin-binding peptide or peptide complex and methods and uses involving them | |
BR112015021785A2 (en) | YEAST PROMOTERS FOR PROTEIN EXPRESSION | |
AR092879A1 (en) | G3P FUSION PROTEINS AS AGENTS OF UNION TO AMILOIDE | |
BR112015022529A2 (en) | cell culture media and antibody production processes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |